BC Extra | Aug 10, 2019
Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

Nektar tumbles on bempegaldesleukin revelation   Nektar Therapeutics (NASDAQ:NKTR) fell $8.65 (29%) to close at $20.92 after reporting during its 2Q19 earnings call late Thursday that it had connected decreasing responses seen in a trial...
BC Week In Review | Jan 11, 2019
Clinical News

Autolus' dual targeting CAR T safe in Phase I/II data for hematological malignancies

Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary data from a pair of open-label, U.K. Phase I/II trials showing that AUTO3 had a manageable safety profile and led to responses among patients with hematological malignancies. AUTO3 comprises...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Extra | Oct 2, 2018
Preclinical News

Carl June, NIBR teams document CAR T resistance

A pair of Nature Medicine studies from CAR T pioneer Carl June and Novartis Institutes for BioMedical Research (NIBR) documented mechanisms that resulted in resistance to Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) or its...
BC Week In Review | Jun 15, 2018
Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
BC Extra | Jun 8, 2018
Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
BC Week In Review | Sep 29, 2017
Financial News

CAR T company Autolus raises $80M series C

On Sept. 26, chimeric antigen receptor (CAR) T cell therapy company Autolus Ltd. (London, U.K.) raised $80 million in a series C round from new investors Cormorant Asset Management and Nextech Invest and existing investors...
BioCentury | Sep 29, 2017
Finance

Fueling up

While crossovers joining Autolus Ltd. ’s series C round don’t necessarily mean the chimeric antigen receptor T cell therapy company will follow fellow Syncona Ltd. (LSE:SYNC) portfolio company Nightstar Therapeutics plc (NASDAQ:NITE) to NASDAQ anytime...
BC Extra | Sep 26, 2017
Financial News

Autolus raises $80M series C

Chimeric antigen receptor (CAR) T cell therapy company Autolus Ltd. (London, U.K.) raised $80 million in a series C round from new investors Cormorant Asset Management and Nextech Invest and existing investors Syncona Ltd., Woodford...
Items per page:
1 - 9 of 9